Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

DexCom Earnings Call: Key Takeaways

Dexcom delivered 11% revenue growth and record new patient starts, raising full-year guidance while navigating a minor PBM contract loss and preparing for a landmark CMS coverage expansion for non-insulin type 2 patients.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Revenue GrowthU.S. revenue up 14% ($970M); International revenue up 5% ($375M).
Mgmt ConfidenceExtremely confident in Long Range Plan; tracking to record new patient year.
Demand VisibilityGlobal new-patient starts near-record levels; active base growth in upper teens.
Margin TrendsGross margin 65.1%, up 380 bps; EBITDA margin 32.4%.
Op. LeverageOperating margin 25.3%; leverage achieved excluding Ireland facility startup costs.
Pricing PowerStable pricing globally; PBM loss expected to be offset by higher pricing.
Vol vs PriceGrowth driven by record volume/new starts; pricing environment remains stable.
Segment GrowthType 2 non-insulin segment seeing largest share gains in U.S.
New ClientsAcquiring European distributor to go direct; record new patient starts.
Capex & DebtCompleted $1B share repurchase; new $1B authorization; Ireland facility commercial production.
RegulatoryAwaiting CMS Type 2 non-insulin coverage decision expected by year-end 2026.
CommentaryFocusing on 'Dexcom Direct' to bypass PBM restrictions and maintain access.
New LaunchesStellow app redesign; G7 15-day system; Canada launch November 2026.

Growth

Worldwide revenue grew 11% to $1.34B; U.S. revenue grew 14% to $970M.

Outlook

Raised 2026 revenue guidance to $5.20B-$5.25B (12-13% growth); targeting 24% operating margin.

Risks

CVS PBM contract loss affecting <4% of U.S. revenue; management used vague 'remuneration' language regarding pricing.

Source

The company's earnings call, NASDAQ: DXCM, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

Dexcom Inc: key numbers

Share price
$81.61Close, Nov 16
Market cap
$30.4B
Shares outstanding
372.95MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Surgical & Medical Instruments & ApparatusSIC 3841

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Dexcom Inc

All →
5:23 PM ET 10-Q
Financial Results ▶ Call

Dexcom Q3 2026 Results: Net Income $275M, Down 3.1% YoY

DexCom reported revenue of $1.34 billion for the third quarter of 2026, representing growth over the $1.21 billion reported in the prior year period. Net income for the nine months ended September 30, 2026, increased to $723.7 million compared to $569.0 million in 2025, driven by higher gross profits and operating income.

Key figure
Net income $275M · -3.1% YoY
4:04 PM ET 8-K
Financial Results

Dexcom Financial Results

Dexcom reported Q3 2026 revenue of $1.34 billion, representing 11% year-over-year growth, and raised its full-year 2026 revenue guidance to $5.20-$5.25 billion. Alongside the results, the company announced that its Board of Directors authorized a new $1.0 billion share repurchase program effective through December 31, 2027.

“This quarter, we continued to build momentum across the business, delivering strong revenue growth and margin progression, strengthening our clinical evidence, and advancing key product and operational initiatives. This performance enabled us to again raise our full-year revenue and operating margin guidance and reinforces our confidence in our ability to deliver on the long-term objectives we outlined at Investor Day.”

Jake Leach, Dexcom’s president and CEO
7:08 PM ET Form 4
Insider Selling

Dexcom EVP Chief People & Culture Off Sadie Stern Sells $202K of Stock

Sadie Stern, EVP Chief People & Culture Off, sold 2,565 shares of Dexcom Inc at $78.62 a share, worth $202K in total on Oct 27, 2026. Shares held after the trade: 120,913 (-2.1%).

Value
$202K
Shares
2,565
Price
$78.62
Role
EVP Chief People & Culture Off
Holding change
-2.1%
Trade date
Oct 27, 2026
6:43 PM ET Form 4
Insider Selling

Dexcom EVP Chief Legal Compliance Off Michael Jon Brown Sells $145K of Stock

Michael Jon Brown, EVP Chief Legal Compliance Off, sold 1,700 shares of Dexcom Inc at $85.48 a share, worth $145K in total on Oct 15, 2026. Shares held after the trade: 98,185 (-1.7%).

Value
$145K
Shares
1,700
Price
$85.48
Role
EVP Chief Legal Compliance Off
Holding change
-1.7%
Trade date
Oct 15, 2026
4:15 PM ET Form 4
Insider Selling

Dexcom EVP Chief People & Culture Off Sadie Stern Sells $221K of Stock

Sadie Stern, EVP Chief People & Culture Off, sold 2,565 shares of Dexcom Inc at $86.15 a share, worth $221K in total on Sep 28, 2026. Shares held after the trade: 123,478 (-2.0%).

Value
$221K
Shares
2,565
Price
$86.15
Role
EVP Chief People & Culture Off
Holding change
-2.0%
Trade date
Sep 28, 2026
4:27 PM ET Form 4
Insider Selling

Dexcom Insider Nicholas Augustinos Sells $680K of Stock

Nicholas Augustinos sold 8,089 shares of Dexcom Inc at $84.02 to $84.04 a share (average $84.04) in 2 transactions, worth $680K in total between Sep 14, 2026 and Sep 15, 2026. Shares held after the trade: 29,293 (-18.2%).

Value
$680K
Shares
8,089
Average price
$84.04
Holding change
-18.2%
Trade date
Sep 14, 2026 to Sep 15, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.